Alta Innovations is pleased to announce it has entered into a new licence agreement with Cytox Limited, a University of Birmingham spinout company developing laboratory services for the in-vitro assessment of risk of dementias such as Alzheimer's disease.
The licence agreement covers new intellectual property developed by Dr Zsuzsanna Nagy in the College of Medical and Dental Sciences at the University of Birmingham. These developments include methods for diagnosing conditions such as Alzheimer’s disease by exploiting the expression of certain sensitive genes in the mTOR pathway – the dysfunction of which has recently been found to be associated with the disease.
The new licence agreement follows significant investment raised by the company earlier in the year which allows the company to further its development of assays, deliver near-term revenue opportunities and conduct prospective clinical studies.
Dementia describes a collection of symptoms that are caused by disorders, including Alzheimer’s disease, which affect the brain, thinking, behaviour and the ability to perform everyday tasks. It is estimated that there are 35 million people living with dementia worldwide but because dementia is challenging to identify, a significant proportion remain undiagnosed and untreated. Successfully identifying patients at risk as early as possible may improve patient outcome and advance the search for improved treatments.
About Cytox Limited
Cytox Limited is a UK company developing diagnostic and prognostic services for neurodegenerative disorders. Cytox currently provides biomarker services, based on its phenoTOR™ assay, to pharmaceutical industry clients conducting clinical trials with drugs for the treatment of Alzheimer's disease (AD) and mild cognitive impairment (MCI). Its blood tests are used to predict which patients with MCI will develop AD, which allows treatment in the earliest stages of AD. The biomarkers are based on the cell cycle hypothesis of AD discovered by Dr. Zsuzsanna Nagy. This service enables patient stratification to enhance drug discovery and efficacy trials by means of a simple blood test, analysed in Cytox’s testing laboratory.
Posted on Thursday 26th September 2013